This website is being reviewed for updates. Some information is offline. We apologize for any inconvenience.
Skip to main content
Rural Health Information Hub
Rural Health Information Hub

Rural Pharmacy and Prescription Drugs – News

News stories from the past 60 days.

Feb 19, 2025 - Notice from the Drug Enforcement Administration and U.S. Department of Health and Human Services (HHS) delaying the January 17, 2025, final rules titled "Expansion of Buprenorphine Treatment via Telemedicine Encounter" and "Continuity of Care via Telemedicine for Veterans Affairs Patients" in accordance with the January 20, 2025, presidential memorandum titled "Regulatory Freeze Pending Review." These final rules will now be effective March 21, 2025. Comments regarding the delayed effective date are due by February 28, 2025.
Source: Federal Register
Feb 11, 2025 - Notice from the U.S. Department of Health and Human Services (HHS) delaying the effective date of the December 13, 2024, final rule in accordance with the January 20, 2025, presidential memorandum titled "Regulatory Freeze Pending Review." The final rule is now effective April 14, 2025, and the compliance date is also delayed until April 14, 2028.
Source: Federal Register
Jan 17, 2025 - Notice of final rule from the Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) amending their regulations to increase access to buprenorphine treatment for opioid use disorders (OUD) through a telemedicine encounter. This rule expands the circumstances under which individual providers are authorized to prescribe buprenorphine for OUD via telemedicine, including an audio-only telemedicine encounter. This final rule is effective February 18, 2025.
Source: Federal Register
Jan 17, 2025 - Notice of proposed rulemaking from the Drug Enforcement Administration (DEA) proposing regulatory changes aimed at expanding patient access to controlled substance medications via telemedicine while mitigating the risks of diversion associated with such expansion. Proposed changes would establish a Special Registration framework and authorize three types of Special Registration that would allow more comprehensive prescribing, including prescribing of Schedule II and narcotic and non-narcotic controlled substances in limited circumstances, by properly registered physicians and mid-level practitioners and dispensing by online telemedicine platforms that constitute covered online telemedicine platforms. Comments are due by March 18, 2025.
Source: Federal Register
Last Updated: 2/14/2025